Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, GeneMachines, Inpharmatica

Premium

Affymetrix has added a number of arrays to its catalog, including an Arabidopsis ATH1 array containing 22,500 probe sets that represent about 24,000 genes, an E. coli antisense array covering more than 4,200 known open reading frames, a P. aeruginosa array representing the annotated genome of strain PA01, and a C. elegans array including 22,500 transcripts.

GeneMachines of San Carlos, Calif., has published an application note detailing the production of oligonucleotide microarrays by printing 50-mers onto OmniGrid Alehyde slides. The publication is available from the company on request.

London-based Inpharmatica has launched Biotech Biopendium, a proteome annotation resource with applications in microarray analysis. Companies have to license the technology for a minimum of two years but do not need to buy and run a server and Oracle license because of a hosted model. Individual research tools are available; modules include microarray high-throughput annotation processing, an open schema, proprietary data integration to the Biopendium, and GT Interactiv to provide functional annotation for novel sequences.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.